Skip banner and top navigation
NHLBI Logo and Link
National Heart, Lung, and Blood Institute: People, Science, Health
 HOME  SITE INDEX  CONTACT US
  
  Patient Recruitment - Lymphoma
TIPS     ADVANCED SEARCH
 

Research Studies        
Alemtuzumab (Campath) for T-LGL Lymphoproliferative Disorders   HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome   Stem Cell Transplant to Treat Lymphoma  
Escalating Doses of ON 01910.Na for Lymphoma   Ofatumumab for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma   Stem Cell Transplant for High Risk Patients with Lymphoma

Lymphoma Research Study

Alemtuzumab (Campath) for T-LGL Lymphoproliferative Disorders

Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders. The study drug, a monoclonal antibody, may help increase blood counts and reduce the number of abnormal T cell large granular lymphocytes. If eligible to participate, consenting subjects will receive an intravenous infusion of study medication alemtuzumab (Campath) once a day for 10 days. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.

If you have been diagnosed with T-LGL and are 18 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-496-4462 or email us at BloodStudy@nhlbi.nih.gov

 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information
 

 

Lymphoma Research Study

Escalating Doses of ON 01910.Na for Lymphoma

Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Prolymphocytic lymphoma (PLL), or Waldenstrom's Macroglobulinemia (also known as lymphoplasmacytic lymphoma or (WM). The study drug, ON01910.Na is classified as mitotic inhibitor and works by interrupting the life cycle of lymphoma cells. Consenting subjects will receive 2 days of drug infusion once every other week (1 cycle) for a minimum of 2 cycles. Subjects without toxicity will have the option to continue the regimen for 2 additional cycles, after which if there is evidence of response, subjects may continue the regimen indefinitely.

If you are between the ages of 18 and 99 and have been diagnosed with MCL, SLL, PLL or WM and have failed to respond to, relapsed following, are not eligible for, or opted not to participate in other standard of care treatment options you may be able to participate in a clinical trial. This study will determine what dose and which dosing schedule of this new drug is safe. We will also evaluate whether or not this drug can slow progression of your illness, improve adenopathy, improve blood counts and/or reduce the need for transfusions of blood and/or platelets.

To find out if you qualify, please call our study coordinator at 301-402-0797 or email us at BloodStudy@nhlbi.nih.gov
 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 

Lymphoma Research Study

HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome

This research is with the Stem Cell Transplant Program investigating the use of allogeneic (donor) stem cell transplantation in patients with mycosis fungoides/Sezary syndrome who have no reasonable expectation of cure from available therapy. The transplant procedure usually involves the use of chemotherapy and replacement of bone marrow cells from a donor family member. Most of the procedures, including the transplant, are performed in the outpatient setting. Participants will have regularly scheduled follow-up monitoring visits for up to 5 years. Provisions for lodging and local travel will be provided consistent with NIH guidelines. There is no charge for medications, laboratory tests, examinations, procedures and/or clinic visits performed as part of this study.If you have any questions about this study, contact the research Coordinator, Tel. No. 301.594.8013 or BloodStudy@nhlbi.nih.gov

 
Email This Study To A Friend       View/Print PDF Version Of This Study

Disease and Treatment Information
 

 

Lymphoma Research Study

Ofatumumab for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma

The purpose of this study is to evaluate the efficacy of ofatumumab in combination with chemotherapy for previously untreated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma(SLL). Ofatumumab is FDA approved for treating CLL/SLL that is not responsive to other drugs.

Participants will receive treatment at the NIH Clinical Center Day hospital and will be regularly scheduled for clinic visits at the NIH to evaluate the response to treatment. There is no charge for study-related medications, laboratory tests or examinations. Financial support towards the cost of lodging and travel is available based on NIH guidelines.
For questions about this study, please contact the research coordinator, Tel. No. 301- 402-0797 or BloodStudy@nhlbi.nih.gov

 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information
 

 

Lymphoma Research Study

Stem Cell Transplant to Treat Lymphoma

If you or someone you know is diagnosed with Non- Hodgkin's lymphoma or Mantle Cell lymphoma, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.

To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov

 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 

Lymphoma Research Study

Stem Cell Transplant for High Risk Patients with Lymphoma

If you have been diagnosed with Non-Hodgkin's lymphoma or Hodgkin's Disease you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.

You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft- versus-host disease.

We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.

To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov

 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 
 
Spacer

NHLBI HOME · ACCESSIBILITY INFORMATION · NHLBI AT THE CLINICAL CENTER · PRIVACY STATEMENT · WEB TECHNICAL CONTACT